AKT1 and melanoma: The phosphatidylinositol 3-kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathways, which are often activated in melanoma, play a crucial role in conferring resistance to targeted therapy, immunotherapy, and chemotherapy [28,29,30,31].